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H U M A N  G E N E T I C S
A novel P300 inhibitor reverses DUX4-mediated global 
histone H3 hyperacetylation, target gene expression, 
and cell death
Darko Bosnakovski1,2,3, Meiricris T. da Silva1,2*, Sithara T. Sunny1,2, Elizabeth T. Ener1,2,  
Erik A. Toso1,2, Ce Yuan4, Ziyou Cui1,2, Michael A. Walters5, Ajit Jadhav6, Michael Kyba1,2†
Facioscapulohumeral muscular dystrophy (FSHD) results from mutations causing overexpression of the transcription 
factor, DUX4, which interacts with the histone acetyltransferases, EP300 and CBP. We describe the activity of a 
new spirocyclic EP300/CBP inhibitor, iP300w, which inhibits the cytotoxicity of the DUX4 protein and reverses 
the overexpression of most DUX4 target genes, in engineered cell lines and FSHD myoblasts, as well as in an FSHD 
animal model. In evaluating the effect of iP300w on global histone H3 acetylation, we discovered that DUX4 over-
expression leads to a dramatic global increase in the total amount of acetylated histone H3. This unexpected 
effect requires the C-terminus of DUX4, is conserved with mouse Dux, and may facilitate zygotic genome activation. 
This global increase in histone H3 acetylation is reversed by iP300w, highlighting the central role of EP300 and 
CBP in the transcriptional mechanism underlying DUX4 cytotoxicity and the translational potential of blocking 
this interaction.
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD), one of the most 
prevalent neuromuscular genetic disorders (1), is caused by loss of 
epigenetic repression of the D4Z4 macrosatellite repeat at 4qter 
(2–4). When this occurs together with a permissive allele of distal 
sequence, which provides a polyadenylation signal (5), the D4Z4 
transcript is stabilized, and the DUX4 protein encoded by this tran-
script (6) is expressed. DUX4 is momentarily expressed in early 
cleavage–stage embryos at the onset of zygotic gene expression (7–9) 
but is not normally expressed in muscle. High levels of DUX4 
expression lead to death of myoblasts (10, 11) and other cell types 
(10, 12), while low levels of expression inhibit myogenic differenti-
ation (10, 13); thus, pathological mechanisms explaining muscle 
loss that involve both death of myofibers and impaired regeneration 
have been postulated. Mouse models, in which DUX4 is expressed in 
skeletal myofibers, show muscle pathologies (14–16). In FSHD-affected 
individuals, expression levels of DUX4 are extremely low, as monoclonal 
antibodies have to date failed to detect DUX4 by immunostaining 
of FSHD biopsies; however, the presence of DUX4 can be inferred 
by RNA sequencing (RNA-seq) of biopsies, where average levels of 
a panel of DUX4 target genes are elevated in FSHD biopsies com-
pared to control biopsies (17).
Mechanistically, it has been shown that the DUX4 N terminus, 
containing two homeodomains, wraps around one complete turn of 
the DNA double helix (18), while the C terminus recruits the histone 
acetyltransferases (HATs) p300 and CBP (CREB binding protein), 
which results in local acetylation of H3K27 and expression of nearby 
target genes (19). The involvement of p300/CBP suggests a potential 
choke point at which DUX4 activity could be blocked if suitable 
inhibitors that block the DUX4-p300/CBP interaction or inhibit the 
acetyltransferase activity of p300 and CBP could be found. Although 
several compounds have been identified as HAT inhibitors, it has 
recently been shown that the general acceptance and spread of these 
inhibitors through the scientific literature was based on insufficient 
validation, and that as a group, they are nonselective assay interference 
compounds (20), meaning that they affect many pathways and are 
therefore unreliable as chemical probes. For example, the commonly 
used HAT inhibitor C646 (21) shows such high thiol reactivity that, 
besides affecting an array of unrelated targets, its acetyltransferase 
inhibitory activity can be severely diminished by its degradation in 
live cells (22), thus making it unsuitable even for in vitro work.
Next-generation specific p300 inhibitors are being developed 
(23). In this study, we investigate the activity of a new compound, 
iP300w, against the cytopathological activity of DUX4. In the course 
of evaluating iP300w, we found that DUX4 expression leads to an 
enormous global accumulation of acetylated histone H3, i.e., it does 
not redirect HAT activity such that it is lost from histones residing in 
some parts of the genome and gained by histones residing near DUX4 
binding sites but changes the global balance of acetylated:nonacetylated 
histones. We show that iP300w reverses both this global effect and 
the specific ability of DUX4 to induce transcription of its target genes. 
Furthermore, through one or both mechanisms, iP300w protects cells 
from DUX4-mediated cytotoxicity.
RESULTS
A series of spirocyclic HAT inhibitors with selectivity for EP300 was 
recently described in patent WO2016044770 by AbbVie, one of 
which, A-485, has been shown to have antitumor potential in vitro 
and in vivo (23). Before the publication of A-485, we selected a dif-
ferent compound from the same series for synthesis, which we refer 
to as iP300 (Fig. 1A). This compound was prepared as a mixture of 
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eight diastereomers. This mixture displayed an IC50 (median inhib-
itory concentration) of 33 nM versus p300 H3K9Ac in an HTRF 
(homogeneous time-resolved fluorescence) assay. The mixture was 
separated into two diastereomers (v and w; chirality not defined) by 
standard high-performance liquid chromatography. Testing of these 
two diastereomers showed that potent activity resided in only one 
of the two diastereomers, iP300w.
iP300w inhibits DUX4-induced cytotoxicity
To test the effect of iP300w on cells expressing DUX4, we used 
LHCN-M2 immortalized human myoblasts (24) modified with a 
doxycycline (dox)–inducible DUX4 transgene (19). In the presence 
of dox, DUX4 is expressed and most cells die within 48 hours. 
Addition of iP300w to the medium enabled a dose-dependent rescue 
of this toxicity at 1 M and above (Fig. 1, B and C). To exclude any 
effects of iP300w on transcription of DUX4 by the Tet-On system, 
we separated the window of dox treatment with that of iP300w 
treatment. In LHCN-iDUX4 cells, although less effectively than 
with continual dox, a short 2-hour pulse of dox also causes most 
cells to die within 48 hours (Fig. 1B, blue series). Therefore, we 
pulsed cells with dox for 2 hours to allow 2 hours of transcription 
of DUX4, washed to remove dox and stop further accumulation of 
DUX4 mRNA, and provided fresh medium with different doses 
of iP300w. Under these conditions also, iP300w provided substantial 
rescue (Fig. 1B, blue series), demonstrating that its inhibitory effects 
occur at some point after DUX4 transcription. To test whether 
cytoprotective effects were generalizable to other cell types, we tested 
iP300w against 293T-iDUX4 cells and found that it protected these 
cells in a similar manner (fig. S1). We also tested iP300w in murine 
cells: C2C12 myoblasts, which are known to express p300 (25), 
modified with a dox-inducible DUX4 transgene (10), were similarly 
protected (Fig. 1, D and E). In addition, we confirmed that dox does 
not have an effect on cell morphology or proliferation of the 
LHCN-rtTA and iC212 parent cell lines (fig. S2).
iP300w inhibits DUX4-mediated transcription
To investigate the effects of iP300w on DUX4 activity, we performed 
further dox pulse-chase experiments in which dox was applied for 
2 hours, and iP300w was added after dox was removed, i.e., added 
to the chase medium (Fig. 2). In the absence of iP300w, DUX4 protein 
is visible within 1 hour, increases to 4 hours, and begins to decline by 
8 hours. This suggests that both the DUX4 RNA and the protein are 
relatively short-lived (Fig. 2A). Reverse transcription quantitative 
polymerase chain reaction (RT-qPCR) showed that DUX4 RNA 
declined to virtually undetectable levels by 8 hours and that iP300w 
had no effect on stability of the DUX4 message. Notably, in the 
presence of iP300w, the DUX4 protein was similar in abundance 
across the time series until the last time point (8 hours), when it was 
less abundant in the treated arm. Because values were similar before 
this point, this is likely a secondary effect, related to DUX4 toxicity 
reducing the efficiency of protein degradation in the untreated arm, 
although we cannot rule out the less likely possibility that EP300/CBP 
activity stabilizes the DUX4 protein. We then measured the activity 
of DUX4 target genes across this time series. Most target genes are 
increased by DUX4 already at the start of the chase period. After the 
addition of iP300w, their expression was severely blunted, while in 
the control arm, they continued to rise. Some DUX4 target genes were 
more dependent on DUX4-mediated EP300/CBP acetyltransferase 
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Fig. 1. iP300w diminishes DUX4-induced toxicity. (A) Chemical structure of iP300w. (B) Cell viability assay [adenosine triphosphate (ATP) assay] on LHCN-iDUX4 
myoblasts at 48 hours. Red series (Dox-continual): Cells were continually exposed to dox (200 ng/ml) for the full 48 hours and treated with serial dilutions of iP300w. Blue 
series (Dox-2-hr. pulse): Cells were induced for 2 hours with dox (200 ng/ml) and then washed, and medium was replaced with dox-free medium containing different 
concentrations of iP300w. Green series (Control): Noninduced LHCN-iDUX4 cells were treated only with different concentrations of iP300w. Data are presented as fold 
difference compared to the control untreated cells (n = 8). (C) Morphology of LHCN-iDUX4 cells after 48 hours with continual dox (200 ng/ml) induction and treatment 
with iP300w (1 M). (D) ATP assay on iC2C12-DUX4 at 48 hours of induction with dox (500 ng/ml) and treatment with various concentrations of iP300w, as in (B). 
(E) Morphology of iC2C12-DUX4 cells at 48 hours of continual dox (500 ng/ml) induction and iP300w (1 M) treatment. Concentrations of dox for both cell lines were 
determined to provide rapid cell death within 48 hours of induction.
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Fig. 2. iP300w disables transcription of DUX4-induced target genes. (A) Western blot for DUX4 and RT-qPCR for DUX4 target genes in LHCN-iDUX4 cells pulse induced for 
2 hours with dox (200 ng/ml) and then treated with 0.1 M iP300w. Protein and RNA samples were harvested at 1, 2, 4, and 8 hours of treatment with iP300w. Data represent 
means ± SEM; ****P < 0.0001, **P < 0.01, and *P < 0.05 by two-way analysis of variance (ANOVA) with Tukey’s post hoc test. Results are presented as fold difference compared 
to GAPDH (n = 3). (B) RNA-seq in LHCN-iDUX4 cells induced for 12 hours with dox (200 ng/ml) and treated with 0.25 M iP300w. Left: Total gene expression given as log2 fold 
change of dox-treated versus control cells on the x axis and iP300w + dox–treated cells versus controls on the y axis. Middle: Same analysis showing only presumed DUX4 
direct targets, defined as at least eight-fold up-regulated by 6 hours (from the Choi et al., 2016 dataset) and with a DUX4 chromatin immunoprecipitation sequencing 
(ChIP-seq) peak within 10 kb of the transcription start site. Right: Effect of iP300w on all strongly up-regulated DUX4 target genes (defined as all genes up-regulated by dox at 
least eight-fold in the current 12-hour dataset), organized by magnitude of the iP300w effect. The great majority of these are down-regulated by iP300w. In all panels, color indicates 
the level of gene expression. (C) RT-qPCR for DUX4 and DUX4 target genes in myotubes from three different FSHD myoblast clonal cell lines (2, A2, and 12) after 12 hours 
of treatment with 0.25 M iP300w (n = 9). ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05 by two-way analysis of variance (ANOVA) with Tukey’s post hoc test.
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activity (e.g., LEUTX) than others (e.g., ZSCAN4). Similar effects 
were observed in cells that were continually induced with dox for 
8 hours (fig. S3). iP300w inactivation of DUX4-induced target genes 
was not cell line specific, as the same effect was observed in other 
myogenic (RD-iDUX4) and nonmyogenic (A204-iDUX4 and 293T- 
iDUX4) cell lines (fig. S4, A and B).
iP300w blocks up-regulation of most DUX4 target genes
We next performed RNA-seq on immortalized human myoblasts 
expressing DUX4 in the presence or absence of iP300w. At 12 hours 
after induction, we observed up-regulation of numerous DUX4 
target genes, as well as many down-regulated genes, as recently 
described (26). However, in the presence of iP300w, the degree of 
up-regulation of most of the DUX4 targets was severely diminished 
(deviation of points from the diagonal to the right of center, Fig. 2B). 
This skewing was not present for most of the down-regulated genes, 
indicating that their down-regulation is not dependent on p300, i.e., 
for the most part, transcriptional down-regulation is not the second-
ary effect of overexpression of certain DUX4 target genes. This is 
consistent with the recent finding that DUX4-mediated down- 
regulation is not dependent on its C terminus (26).
iP300w erases the DUX4-mediated transcriptional 
fingerprint in FSHD myoblasts
We next tested the effect of inhibiting EP300/CBP activity in FSHD 
myotubes using cell lines from a panel of immortalized myoblasts 
carrying a contracted D4Z4 array with three repeats (27). When 
preformed myotubes from three independent lines were exposed to 
0.25 M iP300w for 12 hours, expression of DUX4 target genes was 
severely attenuated (Fig. 2C). Because endogenous DUX4 was ex-
pressed before adding iP300w, mRNA from target genes is already 
present at the time of iP300w addition; thus, this assay will vary 
from gene to gene, depending on the stability of the transcript. 
Notably however, ZSCAN4 was strongly inhibited, despite it being 
only weakly p300 dependent in the cells with inducible DUX4. 
Expression of DUX4 itself was unaffected in two of the three cell 
lines and only moderately affected in the other. Similar results were 
observed at the myoblast level (fig. S5A); however, effects were less 
pronounced, presumably because levels of DUX4 expression are 
lower in myoblasts than in myotubes. The effectiveness of iP300w 
on DUX4 activity was time and dose dependent (fig. S5, B and C).
iP300w impairs DUX4-mediated transcription in vivo 
in the iDUX4pA FSHD mouse model
The experiments performed in cell culture suggested that iP300w 
effectively negates the transcriptional activity of DUX4. To test the 
potential in vivo activity of iP300w, we used the iDUX4pA mouse 
model (14). Four-week-old female mice were given a 12-day treat-
ment of a low dose of dox (5 mg/kg) with or without iP300w 
(0.3 mg/kg), delivered intraperitoneally. At this dose of dox, signif-
icant muscle loss was only observed in the quadriceps muscle, although 
the gastrocnemius + soleus trended toward a lower muscle mass; 
both effects were reversed by iP300w (Fig. 3A).
Our previous work showed that DUX4 expression led to the ac-
cumulation of fibroadipogenic progenitors (FAPs) within skeletal 
muscle (14); therefore, we evaluated mononuclear cells from whole 
muscle digests for FAPs by fluorescence-activated cell sorting (FACS) 
for CD45neg CD31neg Itga7neg PDGFR+ cells (28, 29). This revealed 
the expected significant increase in FAPs provoked by DUX4, but 
FAP numbers were significantly reduced in the presence of iP300w 
(Fig. 3, B and C). In addition to these phenotypic changes, we ob-
served changes in gene expression of DUX4 targets (Myo1g and 
Wfdc3), as well as genes indicative of a fibrotic response (Collagens 1 
and 3 and Tgfb1; Fig. 3D and fig. S6). These data show that the strategy 
of p300/CBP inhibition to inhibit the pathogenic changes caused 
by DUX4 has the potential to work in vivo.
DUX4 drives a global hyperacetylation of histone H3
Previous work on the global distribution of H3K27Ac in response 
to DUX4 led to the hypothesis that DUX4 recruited p300/CBP away 
from many of its normal sites of action for it to act in the vicinity of 
DUX4 (19). This was evident from the global altered pattern of 
H3K27Ac in LHCN-M2-iDUX4 human myoblasts. However, these 
chromatin immunoprecipitation sequencing (ChIP-seq) experiments 
are intrinsically normalized to total reads; thus, they cannot detect 
overall changes in global levels of H3 acetylation. In the process of 
evaluating activity of iP300w in DUX4-expressing cells, we evaluated 
overall levels of various histone acetylations in the presence of DUX4. 
This revealed an unexpected and remarkable increase in total levels 
of H3K27Ac and H3K18Ac within 12 hours of initiating DUX4 
expression (Fig. 4A). DUX4 is expressed at extremely low levels in 
FSHD; therefore, it is of interest to evaluate cellular phenotypes at 
very low levels of expression. Although total levels of acetylation 
were not seen to rise within 12 hours when very low doses of dox 
were used, by 48 hours, a dose of dox as low as 3 ng/ml, at which 
DUX4 is virtually undetectable by Western blot, causes a large 
increase in H3K27Ac and H3K18Ac in human myoblasts (fig. S7A). 
The acetylation ability of DUX4 is mediated by its C terminus, i.e., 
the domain that interacts with p300/CBP (Fig. 4B and fig. S7B).
We tested the effect of iP300w on these global acetylation level 
changes and found that this compound completely blocked the 
ability of DUX4 to induce the global increases in H3K27Ac and 
H3K18Ac described above (Fig. 4C and fig. S7C). It also reduced the 
basal level of H3 acetylation even in the absence of DUX4. Of note, 
it had no effect on the total amount of histone H3, nor did it affect 
acetylation of histone H4. The ability of DUX4 to induce global H3 
acetylation was not cell type restricted. We observed similar effects 
in nonmyogenic 293T cells and in murine myoblast cells (iC2C12-
DUX4, figs. S8 and S9A), where iP300w blocked DUX4-induced H3 
acetylation and prevented the increase in expression of DUX4 target 
genes (fig. S9, A and B).
H3 hyperacetylation is a property conserved  
with mouse Dux
Mouse Dux and human DUX4 have diverged substantially in pro-
tein sequence, with highest similarity in their homeodomains, as 
well as two short stretches of similarity within their C termini (30). 
These C-terminal similarities are within the previously defined 
98–amino acid EP300/CBP-interacting domain of DUX4 (19), suggesting 
that these two proteins may engage similar transcriptional mecha-
nisms. To test whether mouse Dux expression leads to a similar 
global increase in acetylated histone H3, we evaluated both human 
and mouse myoblasts modified with inducible mDux transgenes. 
We generated a human LHCN-M2 immortalized myoblast derivative 
expressing mDux using the same inducible lentivector strategy 
previously used to deliver DUX4 and made use of a previously 
described mouse cell line, iC2C12-mDux (31). In both cases, addition 
of dox led to a large increase in the total amount of acetylated (K27) 
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H3, an increase that could be reversed by iP300w (Fig. 5A). iP300w 
also prevented mouse Dux from inducing its target genes in both 
human (Fig. 5B) and mouse (Fig. 5C) myoblasts.
DISCUSSION
These studies demonstrate the biological activity of the novel p300 
(EP300/CBP) inhibitor iP300w, with significant advantages over many 
previously described HAT inhibitors (20). The activity of iP300w hints 
at the unique SAR (structure-activity relationship) in this series of com-
pounds, which includes A-485. iP300w contains a spiroimidazolidine-2, 
4-dione and an extra fluorinated stereogenic center relative to 
A-485, which features a spirooxazolidine-2,4-dione. The two com-
pounds also differ in their nitrogen-containing substitution on the 
dihydroindene moiety. Nevertheless, the potent activity of iP300w 
validates its selection for resynthesis and use in the studies described 
here. Previous work showed that an interaction between DUX4 and 
EP300/CBP was essential to DUX4 activity (19) and motivated the 
testing of these novel P300 inhibitors in FSHD cell and animal 
models. Consistent with this rationale, we find that iP300w inhibits 
both DUX4 target gene induction and DUX4-induced cytotoxicity. 
In support of its utility, studies in cell lines demonstrated potent 
activity of iP300w at 1 M, and studies in the iDUX4pA FSHD mouse 
model demonstrated inhibition of DUX4 target gene expression 
at 0.3 mg/kg per day.
In the course of investigating histone acetylation, we found that 
expression of both DUX4 and its homolog, mouse Dux, leads to 
global hyperacetylation of histone H3. Histone H3 acetylation is the 
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Fig. 3. Effect of iP300w on DUX4-induced alterations in vivo. (A) Muscle mass of tibialis anterior (TA), quadriceps, gastrocnemius and soleus, and pectoralis, normalized 
to the body weight (BW) at day 12. iDUX4pA;HSA female mice were daily injected with dox (5 mg/kg, intraperitoneally) with or without iP300w (0.3 mg/kg) (n = 8). Wild-
type (WT) siblings were used as a control (n = 4). (B) Representative FACS analyses for PDGFR in pooled sample from quadriceps, gastrocnemius and soleus, pectoralis, 
and triceps at day 12. (C) Quantification of FACS analyses presented in (B). Data are presented as means ± SEM; *P < 0.05 and ***P < 0.001 by one-way ANOVA with Tukey’s 
post hoc test (n = 3). (D) RT-qPCR on RNA isolated from gastrocnemius at day 12. Note suppression of DUX4 target genes in the iP300w-treated group and reduction of 
expression of markers related to fibrosis. Data are presented as means ± SEM; ****P < 0.001 by one-way ANOVA with Tukey’s post hoc test. Results are presented as relative 
expression to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (n = 3).
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most prominent lysine acetylation in these cells, occurring mainly 
at K27, as well as at K18 in the human system. Although DUX4 
interacts with EP300 and CBP, simple overexpression of an interactor 
would not a priori be expected to increase the global activity of 
EP300/CBP, unless a large inactive fraction of these HATs existed. 
A model of histone modifications based on mass action of acetyl-
transferases envisages a limited pool of acetyltransferase activity 
competitively recruited to different target sites within the genome 
based on the abundance and affinity of the numerous transcription 
factors that interact with EP300/CBP. Thus, while the specific 
domains of enrichment of acetylated histone H3 across the genome 
may change with time related to changes in the constellation of 
competing transcription factors, the overall amount of acetylation 
would be predicted to be largely unchanged and linked to the 
abundance of EP300/CBP. The fact that this is not the case and that 
expression of DUX4 leads to grossly increased frequencies of acetylated 
histone H3 suggests that a large inactive store is present and that its 
activity is somehow released by DUX4, by either direct activation or 
abrogation of negative regulation. Given this marked global increased 
histone H3 acetylation, DUX4 therefore appears to be a powerful 
global epigenetic modulator. It is very interesting in this regard that 
DUX4 and mouse Dux are expressed at the onset of zygotic genome 
activation during mammalian embryogenesis (7, 9). Such a global 
increase in H3 acetylation could potentially facilitate zygotic genome 
activation and may therefore reflect the key conserved activity of 
DUX transcription factors expressed during early embryogenesis.
In contrast to the effect of DUX4 overexpression, the inhibitor 
iP300w drives the opposite response: a severe reduction in the levels 
of histone H3K18 and H3K27 acetylation. It also protects DUX4- 
expressing cells from the cytotoxicity caused by the DUX4 protein 
better than any of the compounds identified to date, from screening 
libraries representing more than 200,000 compounds (32, 33) as 
well as other approaches to inhibit DUX4-mediated toxicity (34). 
The previously published compound A-485 from the same chemical 
series has similar effects in our hands, although being slightly less 
potent than iP300w. This correlation of acetyltransferase activity and 
DUX4 toxicity solidifies the notion that DUX4 activity is mediated 
by EP300/CBP, previously established by showing that the C-terminal 
domain necessary for toxicity interacts with EP300 and CBP (19). In 
looking at the effect of iP300w on DUX4 target gene expression, it is 
clear that the vast majority of DUX4 targets show diminished 
expression; however, the level of suppression of transactivation shows 
A
B
C
Fig. 4. DUX4 induces acetylation on H3 that is reversible by iP300w. (A) Western 
blot analyses for acetylation of H3K27, H3K18, and total lysine in LHCN-iDUX4 
cells induced for 12 hours with various concentrations of dox. Note that increased 
acetylation appears at levels of dox at which DUX4 is still not detectable. (B) Western 
blot analyses for the markers of H3 acetylation in LHCN-iDUX4C cells continually 
induced with dox (200 ng/ml) and treated with 0.25 M iP300w for 12 hours. DUX4C 
is the C-terminal deletion construct of DUX4. (C) Western blot for acetylation and 
methylation of H3 and H4 in LHCN-iDUX4 cells that were continually induced with 
dox (20 and 200 ng/ml) for 12 hours. Cells were continually treated with 0.25 M 
iP300w. Acetylation in LHCN cells was evaluated as an additional control.
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Fig. 5. mDUX induces H3 acetylation that is p300 dependent. (A) Western blot 
analyses for H3K18 and H3K27 acetylation in LHCN-imDux and iC2C12-imDux cells 
continually induced with dox (200 ng/ml) and treated with 0.25 M iP300w for 
12 hours. (B) RT-qPCR for mDux target genes in LHCN-mDux after 12-hour induction 
with dox (200 ng/ml) and 0.25 M iP300w. Data are presented as means ± SEM; 
****P < 0.001 by one-way ANOVA with Tukey’s post hoc test. Results are presented as 
relative expression to GAPDH (n = 3). (C) RT-qPCR for mDux target genes in iC2C12-mDux 
cells after 12-hour induction with dox (200 ng/ml) and 0.25 M iP300w (n = 3).
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some variance across DUX4 targets, and there are a few targets that 
are apparently insensitive, at least in the immortalized human 
myoblasts used for RNA-seq, for example, ZSCAN4. This may indicate 
that some targets, such as ZSCAN4, are alternatively regulated and 
may require another coactivator.
It is notable that iP300w suppressed the DUX4 fingerprint in 
FSHD patient myoblasts, in this case, including ZSCAN4. Together 
with the fact that iP300w treatment led to similar effects on DUX4 
target gene expression in the iDUX4pA mouse model for FSHD, 
this suggests that targeting the EP300/CBP aspect of DUX4 function 
may be a productive approach to therapy for FSHD. Long-term 
treatment with this compound or other HAT inhibitors might be 
expected to have off-target effects; thus, risks would need to be care-
fully weighed against potential benefits for this specific class of in-
hibitors. However, given that DUX4 recruits EP300/CBP through 
its C terminus, compounds that disrupted the DUX4-EP300 or CBP 
interaction would be expected to have similar effects on DUX4 gene 
expression and cytotoxicity as iP300w, but without the off-target 
effects of blocking EP300/CBP activity. The results presented here 
provide the proof of principle for such an approach. Understanding 
the structural features of the DUX4 C terminus–EP300/CBP interaction 
would facilitate this approach and should therefore be a high priority.
METHODS
Cell culture
Immortalized human myoblast LHCN-M2 cell lines and FSHD clonal 
cell lines were cultured in proliferation media [F10 (HyClone) sup-
plemented with 20% fetal bovine serum (FBS) (PeakSerum, Ps-FB3, 
lot 293Q16), 1× 2-mercaptoethanol (Gibco), 10−9 M dexamethasone 
(Sigma-Aldrich), basic fibroblast growth factor (10 ng/ml; PeproTech), 
GlutaMAX (Gibco), and penicillin/streptomycin (Gibco)] at 37°C in 
a 5% CO2 atmosphere. Myogenic differentiation was initiated on 
confluent cell cultures with differentiating media [Dulbecco’s modified 
Eagle’s medium (DMEM)/F12; Corning Cellgro], supplemented with 1× 
Insulin-Transferrin-Selenium (Gibco), 1× non-essential amino acids 
(Gibco), GlutaMAX, and penicillin/streptomycin. 293T, A204-iDUX4, 
RH30-iDUX4, and RD-iDUX4 cells were cultured in DMEM/F12 
supplemented with 10% FBS and penicillin/streptomycin. iC2C12-
DUX4 and iC2C12-mDUX cells were cultured in DMEM (HyClone) 
and 20% FBS.
Antibodies and Western blots
For Western blot analyses, proteins were separated on 10% SDS–
polyacrylamide gel electrophoresis gels and transferred to polyvinylidene 
difluoride membrane. Antibodies were diluted in 5% skim milk in 
TBST (tris-buffered saline with Tween 20) and incubated overnight 
at 4°C. Signal was visualized using Pierce ECL Western blotting 
substrate (Thermo Fisher Scientific).
Antibodies used in the study are as follows: rabbit anti-DUX4 
(RD2-47c, 1:50, R&D Systems), GAPDH–horseradish peroxidase 
(HRP) (1:5000, 60004, Proteintech), mouse monoclonal acetylated 
histone H3 (D-4, 1:250, sc-518011, Santa Cruz Biotechnology), mouse 
monoclonal acetylated histone H4 (E-5, 1:250, sc-377520, Santa Cruz 
Biotechnology), mouse monoclonal histone H3 K9me3 (6F12-H4, 
1:250, sc-130356, Santa Cruz Biotechnology), rabbit anti–histone 
H3 K18Ac [1:500, ab1191 (Abcam) and 9675T (Cell Signaling)], rabbit 
anti–histone H3 K27Ac (1:500, ab, Abcam), rabbit anti–acetylated 
lysine (1:500, 9441S, Cell Signaling), rabbit anti–histone H3 K9 
(1:500, C5B11, Cell Signaling), anti–histone H3 (Poly6019, 1:500, 
601901, BioLegend), and anti–rabbit-HRP (1:5000, 111-035-003, 
The Jackson Laboratory).
ATP assay
Cell lines were plated in a 96-well dish (2000 cells per well) and, the 
following day, induced with dox (200 ng/ml) with and without iP300w 
treatment. ATP assays were performed using CellTiter-Glo Luminescent 
Cell Viability Assay (Promega) according to the manufacturer’s instruc-
tions. Luminescence was analyzed on the POLARstar Optima Microplate 
Reader (BMG Labtech, Offenburg, Germany).
Evaluation of effectiveness of iP300w in vivo
The iDUX4pA mouse model for FSHD was used for this study. 
Four-week-old female mice carrying both the iDUX4pA and HSA-rtTA 
transgenes were injected with dox (5 mg/kg intraperitoneally) in 
phosphate-buffered saline (PBS) for 12 days. Half of these mice further 
received intraperitoneal injections of iP300w (0.3 mg/kg; 0.5 l from 
a 10 mM stock, diluted in 100 l of PBS) per day, while the other 
half received PBS only. Untreated wild-type siblings were used for 
unaffected comparisons.
FACS analyses of FAPs from muscle
Analysis of muscle infiltration with FAPs was performed as previously 
explained (14). Briefly, pooled muscles (tibialis anterior, gastrocnemius, 
soleus, quadriceps, triceps, and pectoralis) were digested with colla-
genase type II and dispase. Mononuclear cells were stained with the 
following antibodies: phycoerythrin (PE)–Cy7–conjugated CD45 
and CD31 (552848 and 561410, respectively; BD Biosciences), PE- 
conjugated PDGFR (562776; BD Biosciences), and allophycocyanin 
(APC)–conjugated rat anti–integrin 7 (67-0010-05; Ablab), resus-
pended in PBS/1% FBS. Samples were run on a BD FACSAria instru-
ment, and data were analyzed using FlowJo (BD Biosciences). All 
experiments were performed on at least three biological replicates.
Animal studies
Mice were maintained in specific pathogen–free conditions under a 
protocol approved by the University of Minnesota Institutional 
Animal Care and Use Committee.
RNA isolation, quantitative real-time RT-PCR (RT-qPCR), 
and RNA-seq
RNA was extracted using an RNA extraction kit (Zymo), and 
complementary DNA (cDNA) was made using 0.75 g of total RNA 
with oligo-dT primer and Verso cDNA Synthesis Kit (Thermo 
Fisher Scientific) following the manufacturer’s instructions. qPCR 
was performed by using Premix Ex Taq (Probe qPCR, Takara) and 
commercially available probes: ZSCAN4, Hs00537549_m1; MBD3L2, 
HS00544743_m1; DUX4, Hs03037970_g1; GAPDH, Hs99999905_m1; 
TRIM43, Hs00299174_m1; LEUTX, Hs01028718_m1; PRAMEF1, 
Hs04401269_sH; CCNA1, Hs00171105_m1; CDK1A, Hs00355782_m1; EGR1, 
Hs00152928_m1; Gapdh, Mm99999915_g1; Myo1g, Mm00617991-m1; 
Wfdc3, Mm01243777_m1; Zscan4c, Mm02581232_m1; Slc34a2, 
Mm01215846_m1; Pramef6, Mm01728753_g1; Tmem92, Mm01299147_m1; 
Usp17lb, Mm04214102_s1 (Applied Biosystems). Endogenous DUX4 
expression in FSHD myoblast cell lines was detected by FAM-labeled 
probe (TCTCTGTGCCCTTGTTCTTCCGTGAA) and primers 
PLH298-PAS-F: CCCAGGTACCAGCAGACC and PLH395-PAS-R: 
TCCAGGTTTGCCTAGACAGCGTC, which target the 3′ splice and 
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polyadenylation site (14). Gene expression levels were normalized 
to that of GAPDH and analyzed with 7500 System Software using 
the ∆∆CT method (Applied Biosystems). RNA-seq libraries were 
prepared using 500 ng of total RNA and the KAPA mRNA Hyper 
Prep Kit following the manufacturer’s instructions. Fifty–base paired 
end sequencing was performed on an Illumina NovaSeq instrument 
at the University of Minnesota Genomics Center.
Bioinformatics
A total of 163,937,137 reads were generated for the samples (mean 
is 20.49 million reads, between 19.35 million and 21.76 million 
reads per sample). The FASTQ files were analyzed using a customized 
pipeline (gopher-pipelines; https://bitbucket.org/jgarbe/gopher-pipelines/ 
overview) developed and maintained by the Minnesota Supercom-
puting Institute. The sequencing quality was checked using FastQC 
v0.11.5 (www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
Low-quality reads were discarded using Trimmomatic v0.33 (www.
usadellab.org/cms/index.php?page=trimmomatic) (35). Reads 
passing quality checks were then aligned to GRCh38/hg38 reference 
genome using HISAT2 v2.0.2 (https://ccb.jhu.edu/software/hisat2/
index.shtml) (36). The transcript abundances were then counted 
using subread v1.4.6 (http://subread.sourceforge.net/) (37). The reads 
were filtered to include genes with counts per million value over 
5 in at least 20% of the samples for subsequent analysis. Sequencing 
data have been deposited in the Gene Expression Omnibus repository 
under accession code GSE130522.
Differential gene expression (DGE) analysis was performed in 
R v3.4.3 using edgeR package (https://bioconductor.org/packages/ 
release/bioc/html/edgeR.html) (38). The DGE genes were visualized 
using ggplot2 package.
Statistics
GraphPad Prism software was used for statistical analyses of the 
data, except where indicated. Differences between groups were 
evaluated by one- or two-way analysis of variance (ANOVA) followed 
by Tukey’s post hoc tests. Differences were considered significant at 
P values of 0.05 or lower.
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